European Primary Care Cardiovascular Society

Heart Failure

Follow the news, literature, and elearning on new developments in the management of Heart Failure.

SGLT2 inhibitor greatly reduced CV risk in HFrEF with or without diabetes

3' education - Sep. 16, 2019 - Paris, France - Prof. John McMurray
DAPA-HF evaluated dapagliflozin in addition to standard therapy in HFrEF patients with or without diabetes, and showed a risk reduction of 26% in worsening of HF and CV death.

ESC 2019 DAPA-HF evaluated dapagliflozin in addition to standard therapy in HFrEF patients with or without diabetes, and showed a risk reduction of 26% in worsening of HF and CV death.

Beta-blockers give benefit in HFrEF in sinus rhythm with renal dysfunction

News - Sep. 4, 2019
The BB-meta-HF group combined double-blind, individual patient-level data and confirmed that beta-blockers are efficient in HFrEF patients in sinus rhythm with moderately-severe renal dysfunction.

ESC 2019 The BB-meta-HF group combined double-blind, individual patient-level data and confirmed that beta-blockers are efficient in HFrEF patients in sinus rhythm with moderately-severe renal dysfunction.

New diagnostic algorithm and therapeutic options in HF management

5' education - Mar. 22, 2019 - Lisbon, Portugal - Peter van der Meer & Monika Hollander
Professor Peter van der Meer & Monika Hollander consider new recommendations in the latest ESC Guidelines on diagnosis and treatment of patients with HF, and the role GPs may play in this process.

EPCCS 2019 Professor Peter van der Meer & Monika Hollander consider new recommendations in the latest ESC Guidelines on diagnosis and treatment of patients with HF, and the role GPs may play in this process.

Validated prediction score for incident HF can be used in primary care setting

Literature - June 17, 2019 - Khan SS et al., - J Am Coll Cardiol. 2019

The PCP-HF score provides sex- and race-specific estimates of 10-year risk of incident HF, based on risk factor information readily available in primary care setting.

GRAND DEBATE | Cather ablation for all patients with HF and AF?

ESC Heart Failure 2019, Athens, Greece
ESC Heart Failure 2019, Athens, Greece

ESC HF 2019 In this debate, Douglas Packer and John Cleland took opposite sides of the statement that all patients with atrial fibrillation and heart failure should receive ablation. With poll.

Stroke risk reduced by factor Xa inhibitor in patients with HFrEF, sinus rhythm and CAD

News - June 7, 2019
A subanalysis of the COMMANDER-HF trial demonstrated that low dose rivaroxaban decreased stroke/TIA risk in patients with HFrEF, sinus rhythm and CAD without increase in major bleeding.

ESC HF 2019 A subanalysis of the COMMANDER-HF trial demonstrated that low dose rivaroxaban decreased stroke/TIA risk in patients with HFrEF, sinus rhythm and CAD without increase in major bleeding.

More patients remaining on spironolactone with potassium binder in resistant hypertension and CKD, with and without HF

News - June 7, 2019
Addition of patiromer to spironolactone showed that a higher percentage of patients remained on spironolactone vs. those on placebo and spironolactone at the start, with no difference between HF or non-HF.

ESC HF 2019 Addition of patiromer to spironolactone showed that a higher percentage of patients remained on spironolactone vs. those on placebo and spironolactone at the start, with no difference between HF or non-HF.

Education, exchange, guidance and interaction during EPCCS Summit 2019

EPCCS Annual CV Summit

EPCCS 2019 Read impressions of the updates on stroke prevention in AF, hypertension, HF and CV risk in diabetes, with emphasis on challenges faced in patients with multimorbidities.

Complexities of managing heart failure

EPCCS Annual CV Summit

EPCCS Annual CV Summit

EPCCS 2019 Read an impression of the presentation of prof. Van der Meer, on the latest recommendations on management of HF, including important aspects to consider in patients with comorbidities.

Slides | Complexities of managing heart failure

Slides (presentation) - Mar. 22, 2019 - Lisbon, Portugal - Prof. Peter van der Meer
**EPCCS 2019** Slides prepared and presented by prof. **Peter van der Meer** (Groningen, The Netherlands), here offered as an educational service.

EPCCS 2019 Slides prepared and presented by prof. Peter van der Meer (Groningen, The Netherlands), here offered as an educational service.

EPCCS

European Primary Care Cardiovascular Society

3' education - Feb. 8, 2019

Learn more about the activities of EPCCS that are aimed at supporting primary care professionals manage their patients with cardiovascular and cardiometabolic disease.

HFpEF: What is it & size of the problem

HFpEF: The essentials to know

10' education - Aug. 27, 2018 - Prof. Adriaan Voors - Groningen, The Netherlands
Prof. Adriaan Voors gives a general overview on the history, epidemiology and prognosis of HFpEF

HFpEF: The essentials to know Prof. Adriaan Voors gives a general overview on the history, epidemiology and prognosis of HFpEF.